



### Company Overview

Syros is committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, Syros is developing tamibarotene, an oral selective RAR $\alpha$  agonist in frontline patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with *RARA* gene overexpression.

### Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression

Apr 9 2024, 7:00 AM EDT

### Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 2 2024, 4:30 PM EDT

### Stock Overview

Symbol	SYRS
Exchange	Nasdaq
Market Cap	147.08m
Last Price	\$5.56
52-Week Range	\$2.0902 - \$8.17

04/16/2024 04:00 PM EDT

### Investor Relations

Syros Pharmaceuticals  
Karen Hunady  
Director of Corporate  
Communications & Investor  
Relations  
[khunady@syros.com](mailto:khunady@syros.com)

Stern Investor Relations, Inc.  
Hannah Deresiewicz  
[hannahd@sternir.com](mailto:hannahd@sternir.com)

### Management Team

#### Conley Chee

President and Chief Executive Officer

#### Jason Haas

Chief Financial Officer

#### Gerald E. Quirk

Chief Legal Officer & Head of Business Development

#### Lisa Roberts

VP Human Resources

#### David A. Roth, M.D.

Chief Medical Officer

#### Kristin Stephens

Chief Development Officer

### Syros Pharmaceuticals, Inc.

35 CambridgePark Drive  
4th Floor  
Cambridge, MA 02140

### Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.